Department of Respiratory and Critical Care Medicine II, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 646000, Sichuan, China.
Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, University of Kansas Medical Center, 3005 Wahl Hall East, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.
J Hematol Oncol. 2020 Jun 5;13(1):69. doi: 10.1186/s13045-020-00898-y.
The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.
广泛期小细胞肺癌（ES-SCLC）患者的预期寿命在过去 2-3 十年间并未得到改善，直到最近两项临床试验（CASPIAN 和 IMpower133）表明，抗程序性死亡配体 1（PD-L1）治疗联合化疗比单独化疗具有生存获益。然而，这种获益相对较小，在其他一些使用免疫疗法的试验中甚至没有观察到，这就提出了在 ES-SCLC 的一线治疗中，最佳化疗免疫联合治疗方案的问题。在这里，我们结合 IMpower133 和 CASPIAN 试验，讨论了几个发人深省的问题。
